Mar 03, 2026 8:00am EST Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
Feb 25, 2026 8:00am EST Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Feb 23, 2026 8:00am EST Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
Jan 28, 2026 8:00am EST Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
Jan 08, 2026 8:00am EST Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
Dec 09, 2025 8:00am EST Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
Dec 02, 2025 8:00am EST Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Nov 20, 2025 8:00am EST Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach